Objectives: The major advantages of Drosophila melanogaster are a well-characterized immune system and high degree of susceptibility to tuberculosis caused by Mycobacterium marinum. The D. melanogaster -M. marinum infection model is gaining momentum as a screening tool because it is genetically amenable, low priced, rapid, technically convenient and ethically acceptable. In this context, the aim of this study was to develop a new, effective D. melanogaster-M. marinum in vivo efficacy model for antimycobacterial drug discovery.
Introduction
Based on the most recent publications, tuberculosis (TB) causes 2 million deaths annually worldwide and more than 2 billion people are infected with Mycobacterium tuberculosis. 1 In addition, the emergence and widespread transmission of multidrug-resistant (MDR) and extensively drug-resistant (XDR) variants of M. tuberculosis have begun to threaten health security around the world. 2 Furthermore, the inability of antibiotics to kill dormant or latent bacilli remains a serious problem in TB control. Therefore, it is necessary to seek new compounds that show potent antimycobacterial activity as well as new forms of therapy.
Recent efforts in antimicrobial drug development have been focused on the use of in vitro or cell culture systems for the selection of new potential drug candidates. However, most pathogens undergo dramatic transcriptional changes when they are transferred from a host to cell culture conditions. 3 Thus, screening of antimicrobial compounds in a host-free system may be less efficient to find compounds that are effective in vivo, or the screening may select compounds that are only effective in vitro and are ineffective against an infection within a host. This problem created a need for the development of a simple and innovative model system for screening in the drug discovery and development pipeline. In this context, recently a number of nonmammalian models of infection (Danio rerio, Arabidopsis thaliana, Drosophila melanogaster and Caenorhabditis elegans, for example) have been developed as attractive alternatives because these simple model systems can offer several advantages in terms of speed, cost, technical convenience and ethical acceptability. 4 -7 Among several non-mammalian model systems, D. melanogaster has been commonly used in microbial pathogenesis studies because it conserves host signalling pathways and tissue physiology that allow for modelling of human host -pathogen interactions. 3 Furthermore, Drosophila recognizes external pathogenic infections, and its ability to cope with specific pathogens is partially shared with higher organisms. For these reasons, D. melanogaster has become a model system for the study of the pathogenicity of various pathogens, including Mycobacterium marinum, Pseudomonas aeruginosa, Staphylococcus aureus and Listeria monocytogenes. 8 -12 Among them, the relatively fast-growing human and animal pathogen M. marinum, a close genetic relative of M. tuberculosis, has been used to study the pathogenesis of TB, because M. marinum causes systemic infections and disease in ectothermic hosts such as fish and frogs. 13, 14 In addition, a low dose of actively growing M. marinum causes a lethal infection in D. melanogaster within a short period of time, and the mechanism of lethality involves reduced insulin signalling and consumption of fat and glycogen stores in wasting condition. Dionne et al. 8 therefore suggest that the D. melanogaster-M. marinum infection model can be used as a genetically tractable model system to study the mechanisms of interaction between mycobacteria and phagocytes, since intracellular M. marinum blocks vacuolar acidification in the host as it does in vertebrate macrophages.
Here, we describe a new simple and rapid preliminary in vivo efficacy model to evaluate antimycobacterial agents by using D. melanogaster and M. marinum. For this purpose we tested several anti-TB drugs that have different mechanisms of action (MOAs) to assess the effectiveness of antibiotics in M. marinum-infected Drosophila. Our results showed an extended life span compared with an untreated group. These data demonstrate the potential of the D. melanogaster-M. marinum in vivo model for testing drug efficacy, which could be placed before mammalian models of infection in highthroughput antimycobacterial drug screening.
Materials and methods
Bacterial strains and culture conditions M. marinum ATCC 927 was grown in Middlebrook 7H9 broth (Difco) supplemented with 0.05% Tween 80 and albumin -dextrose complex (ADC) enrichment and aliquots were frozen at 2808C in 10% glycerol, or on 7H11 agar with 10% oleic acid-albumin-dextrose-catalase (OADC) enrichment (Becton Dickinson) at 298C. To construct the Green Fluorescent Protein (GFP)-expressing M. marinum strain, M. marinum was transformed with the dual reporter plasmid pSMT3LxEGFP (kind gift from Prof. Qian Gao, Fudan University, Shanghai, China) and positive clones were selected on 7H11 agar plates supplemented with 50 mg/mL of hygromycin. P. aeruginosa GFP strain was constructed using a gift from Prof. Howard Ceri (Calgary University, Calgary, Alberta, Canada). The number of cfu per millilitre for M. marinum inoculum was determined using the serial 10-fold dilutions method. Homogenized M. marinum cultures were inoculated onto duplicate 7H11 selective agar plates at 0.5 mL per each of 10 plates. Plates were incubated in sealed, CO 2 -permeable plastic bags at 378C in an atmosphere containing 5%-7% CO 2 . The cfu/mL of inoculum was calculated after 1 week of incubation.
Fly maintenance, injection and antibiotics treatment of infected flies
All experiments were carried out in 5-to 7-day-old adult male D. melanogaster w 1118 flies. The flies were fed and raised at 298C, 65% humidity, on standard yeast cornmeal food. For bacterial infection, the flies were anaesthetized with CO 2 and an aliquot of M. marinum was thawed, diluted 1 :3 in fresh PBS, and then different numbers of M. marinum were injected into the junction area between the ventral and dorsal cuticles using a micro-capillary tube (Sigma). Following infection, the flies were incubated at 298C on fly medium that contained isoniazid, rifampicin, ethambutol, pyrazinamide, amikacin, dinitrobenzamide or ampicillin (dissolved in DMSO) at different concentrations (0, 100 and 500 mg/L). Each survival curve was performed using a total of 20 flies per condition and each experiment was performed in triplicate. The number of dead flies was monitored daily and survival curves and SDs were calculated. Based on Korean law, the research performed in this study on the fruit fly, D. melanogaster, did not need to be approved by an Ethics Committee.
Alamar blue susceptibility assay
The Alamar blue susceptibility assay was performed as described previously. 15 Briefly, each of antimycobacterial agents was diluted in 7H9. Serial 2-fold dilutions of these solutions were prepared in a 96-well plate using 100 mL 7H9. The range of concentrations tested was 200-0.78 mg/L for each of compound. Negative control wells had only the solvent included. Afterwards, the plates were inoculated with 100 mL suspension (1×10 5 cfu/mL of M. marinum ATCC 927) and sealed in plastic bags; incubation was at 298C (for M. marinum ATCC 927) for 5 days. After incubation, 10 mL resazurin working solution was added to each well and the plates were incubated for 24 h at each optimal temperature and the results were read visually. A change in colour of the resazurin from blue to pink indicated reduction of the indicator, and thus bacterial growth. The MIC was defined as the lowest drug concentration that prevented a full colour change of the resazurin from blue to pink.
Determination of bacterial cfu and GFP observation
Individual infected flies were anaesthetized with CO 2 and then placed on ice. To remove surface bacteria, flies were treated with 70% ethanol and then homogenized with a pestle in 100 mL of sterilized H 2 O. Quantitative bacterial count studies using serial dilutions of homogenized flies were performed onto 7H11 agar plates supplemented with 10% OADC enrichment (Becton Dickinson). Plates were incubated for 10 days and colonies were counted to determine the number of cfu per fly. Meanwhile, GFP-expressing M. marinum and GFP-expressing P. aeruginosa in flies were observed with a SteREO Lumar.V12 stereomicroscope (Zeiss) with fluorescence optics.
Haemolymph extraction and liquid chromatographymass spectrometry/mass spectrometry (LC-MS/MS) quantification
Haemolymph was collected as previously described by Broughton et al. and LC-MS/MS was conducted. 16 For the LC-MS/MS quantification, a stock solution of isoniazid was prepared in DMSO at 1 g/L concentrations and working standard solutions were prepared by serial dilution of the stock solution with DMSO at 100, 50, 10, 5, 1, 0.5 and 0.1 mg/L. For the internal standard, verapamil was prepared in acetonitrile at 0.2 mg/ L. Standard samples were prepared by a 100-fold dilution with distilled water. The final concentrations of standard samples were 1000, 500, 100, 50, 10, 5 and 1 mg/L. For drug analysis, 1 mL of haemolymph sample was diluted with 9 mL of distilled water. The standard samples (10 mL) and diluted haemolymph samples (10 mL) were added to a 96-well microtitre plate. The internal standard solution (30 mL) was added to the samples and the plate was left to stand for 10 min at 48C. The samples were transferred to a filtration plate (Solvinert, 0.45 um, Millipore) and centrifuged for 3 min at 440g at 48C. Distilled water (40 mL) was added to the filtrates and the samples were analysed with an HPLC LC-MS/MS system. The Agilent 1200 series HPLC system and the Agilent 6430 QQQ tandem mass spectrometer were used for the quantitative analysis. Chromatographic separations were achieved with Oh et al.
a Zorbax SB-C18 column (2.1×50 mm, 1.8 mm, Agilent) and the column oven temperature was 408C. An isocratic elution was applied using 45% acetonitrile in distilled water with 0.5% trifluoroacetic acid (TFA). The flow rate was 0.2 mL/min and the injection volume was 5 mL. Detection of analytes was performed in electrospray ionization (ESI) (+) multiple-reaction-monitoring (MRM) mode, using the transitions 138.1 to 121.0 m/z. The gas flow rate was 0.2 mL/min and the gas temperature was 3008C. The nebulizer pressure was 20 psi and the capillary voltage was 4000 V. The fragmenter voltage and the collision energy were 155 V and 14 eV, respectively. MassHunter software (Agilent) was used for data analysis.
Results and discussion
Live M. marinum kills D. melanogaster in a dose-dependent manner M. marinum is closely related to M. tuberculosis, the cause of TB in humans, and M. marinum has become an important model species for the study of the very early phases of Mycobacterium infection. 17 Previous studies have shown that M. marinum causes a lethal infection in flies via progressive loss of metabolic stores in the form of fat and glycogen. 17 This result suggests the possibility that the M. marinum -D. melanogaster infection system could be used as an inexpensive and genetically tractable model to study the progression of TB infection. We therefore tested whether this infection model is effective in preliminary in vivo assessment of several conventional and newly discovered antimycobacterial agents. To confirm this hypothesis, the fly survival rate after challenge was determined. Figure 1 shows the survival curves for D. melanogaster after infection with M. marinum at three different inocula. The amount of injected bacteria was calculated using 10-fold dilution, and the flies were infected by pricking them with needles as described in the 'Materials and methods' section. As shown in Figure 1 , the flies infected with live M. marinum that had been grown to the early stationary phase (OD 600 ¼ 3.0) died within about 13 days ( 25 cfu/100 nL), and this result was in accordance with previous reports by Dionne et al. 8 None of the flies infected with 100 and 50 cfu survived to 10 days or 12 days, respectively. Conversely, 100% of the flies injected with heat-killed M. marinum survived, suggesting that lethal infection requires the presence of live bacteria and indicating that living cells of M. marinum kill flies in a dose-dependent manner.
M. marinum infection in D. melanogaster can be cured with antimycobacterial agents
The D. melanogaster infection model has previously been used to test the efficacy of antibiotics against S. aureus. Flies infected with S. aureus were cured by treatment with effective antibiotics such as methicillin. 11 Therefore, we tested the possibility of utilization of the D. melanogaster-M. marinum infection model for assessment of TB treatments. The antimycobacterial agents isoniazid, rifampicin, ethambutol, pyrazinamide, amikacin, dinitrobenzamide and ampicillin were tested. Each drug selected for trial has a different MOA as a bacterial killing/growth inhibiting agent and has been used for TB control or has been placed in the TB drug discovery pipeline. A brief summary of the MOA of each compound used is as follows: ethambutol interferes with cell-wall biosynthesis through inhibition of arabinosyl transferase (EmbB), which is a membrane-associated enzyme involved in the synthesis of arabinogalactan;
18 isoniazid interferes with cell-wall biosynthesis by inhibiting enoyl-acyl carrier protein reductase (InhA), which is an important enzyme for the elongation of longchain mycolic acids; 19 pyrazinamide interferes with cell-wall biosynthesis by inhibition of fatty acid synthase I (FAS-I), which is involved in the synthesis of short-chain mycolic acids. Furthermore, the active form of pyrazinamide, pyrazinoic acid (POA), interferes with membrane bioenergetics and binds to the ribosomal protein S1 (RpsA). POA also inhibits trans-translation, a key cellular process by which damaged proteins are managed and non-functioning ribosomes are rescued; 20 -23 rifampicin interferes with RNA transcription by binding to the b-subunit of the DNA-dependent RNA polymerase enzyme complex and inhibits transcription of messenger RNA; 24 amikacin is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 70S ribosomal unit, making M. tuberculosis unable to grow; 25 dinitrobenzamide is a newly discovered member of a new class of potent antitubercular drugs that target phosphoribose 2 ′ -epimerase, an enzyme essential for the growth and survival of M. tuberculosis.
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Thus, we examined whether M. marinum-infected flies could be cured with antibiotics that have different MOAs. Each compound was mixed with fly medium and fed to flies after M. marinum infection ( 25 cfu/100 nL). The survival rates of M. marinum-infected flies were observed for 15 days while they were being fed standard yeast cornmeal food containing 0, 100 and 500 mg/L of isoniazid, rifampicin, ethambutol, pyrazinamide, dinitrobenzamide, amikacin or ampicillin. The results shown in Figure 2 present the survival rates of the drug-treated fly cultures compared with the growth of the untreated fly culture controls. As expected, rifampicin, amikacin and dinitrobenzamide were very effective at a concentration of 500 mg/L; the fly survival rate at concentrations ,500 mg/L of all three compounds ranged from 73% to 87% at 15 days (Figure 2a-c) . Rifampicin shows bactericidal activity against a Oh et al.
wide range of microorganisms by inhibiting the initiation of RNA synthesis. Dinitrobenzamide, newly identified in a high-throughput, fluorescence microscopy-based screening of a library of small molecules, inhibits the synthesis of decaprenylphosphoryl-D-arabinose synthesis catalysed by decaprenyl-phosphoribose 2 ′ epimerase (DprE1/DprE2), which is essential for M. tuberculosis growth. 26 In addition, amikacin is an important bactericidal drug used to treat MDR-TB and has shown excellent activity against atypical mycobacteria as well. These three different compounds showed similar bactericidal activity in our system, as indicated by the results of the M. tuberculosis treatment. However, these three compounds showed no activity at lower doses, such as at 100 mg/L.
Unexpectedly, we also observed strong survival rates of infected flies treated with isoniazid at a concentration of 500 mg/L (Figure 2d ). However, there is one considerable difference between our results and those of previously published studies. Although isoniazid is highly effective against M. tuberculosis (bactericidal at low concentrations), most strains of M. marinum have been found to be resistant to isoniazid in in vitro experiments. 27 However, our results showed an in vivo result that was different from the results obtained in vitro. In our study, isoniazid showed strong antimycobacterial activity at a high dose (500 mg/L) in M. marinum-infected flies, but did not show any activity in the Alamar blue cell-free assay (data not shown). This apparent discrepancy can be explained by the amount of isoniazid used in our experiment, as we used 500 mg/L as an effective point. However, this amount is greatly in excess of the known isoniazid MIC for M. marinum (16 mg/L). 28 Thus, to determine the exact amount of isoniazid delivered, we analysed the isoniazid concentration in fly haemolymph using the LC-MS/MS method. A total of 200 flies were fed for 10 days with fly medium plus isoniazid (500 mg/L) and the average isoniazid concentration in the body fluid of the flies was determined. The LC-MS/MS results showed that the isoniazid concentration ranged from 4.86 to 5.15 mg/L/fly in haemolymph. Although this amount of isoniazid is extremely low compared with the in vitro isoniazid MIC, this concentration was sufficient to inhibit the growth of M. marinum in the D. melanogaster in vivo model system. Additional experiments need to be carried out in order to clarify the mechanism by which isoniazid kills M. marinum in vivo in relation to the D. melanogaster immune response. However, we anticipate that the haemolymph delivered concentration is presumably enough to kill the bacteria that were localized in the fly body.
In contrast, pyrazinamide was not effective against M. marinum in our system, likely due to the Drosophila haemocyte pH (Figure 2e) . It is well known that pathogens and other extracellular material contained in phagosomes are eventually degraded via phagosome-lysosome fusion in an acidic environment. Phagosomes are thought to acquire proteolytic enzymes and a lower pH during the process of phagosome maturation through a series of fleeting interactions with endocytic compartments. 29 However, it is also well known that pyrazinamide is almost completely inactive at a neutral pH, but inhibits mycobacteria in acidic conditions ( pH 5.5). 30, 31 The pH range of adult flies is described to be pH 6.92-6.70, which is considered to be somewhat neutral; no detailed information is available concerning the pH range of Drosophila haemocytes. Furthermore, the acidification process has not been studied in Drosophila haemocyte phagosomes. 32, 33 Therefore, we speculate that pyrazinamide may be inactivated by the neutral pH range in adult flies. A much more accurate and tightly controlled experiment will be necessary to measure the intraphagosomal pH range in flies. Lastly, the survival rate with the use of ethambutol was lower than that with the use of isoniazid, rifampicin, amikacin and dinitrobenzamide, but higher than that with the use of pyrazinamide (Figure 2f ). In vitro experiments have shown that ethambutol alone does not prevent disease progression, and in vivo experiments with guinea pigs have revealed that it has no apparent influence on the bactericidal activity of isoniazid or rifampicin. 34, 35 Thus, ethambutol was unlikely to contribute to the sterilization of TB lesions, but it might assist in the prevention of drug resistance. 34, 35 Our results support the previous result regarding ethambutol efficacy. Thus, our D. melanogaster-M. marinum infection model simulates the behaviour observed in animal model systems.
The specificity of the Drosophila model could be improved by using two different approaches. First, the non-antimycobacterial compound ampicillin was tested against M. marinum -D. melanogaster infection as a negative control because the resistance of mycobacteria to b-lactam antibiotics is attributed to their ability to synthesize b-lactamase. 36 As shown in Figure 2 (g), the growth of M. marinum was not inhibited in the presence of ampicillin. Therefore, these results indicate that the D. melanogaster -M. marinum infection/curing model could be useful for TB-specific drug screening. Second, the antimycobacterial compound isoniazid was tested against the unrelated bacterial pathogen P. aeruginosa PAO1. PAO1 is a particularly virulent pathogen, and its pathogenicity was successfully tested previously in the Drosophila host model. 9 For consistency, we used the same method for both pathogens, and PAO1 cells were infected as described previously, except that flies were fed for 5 days with isoniazid-containing food. 9 Because wild-type PAO1 killed host flies within a short time (50% mortality within 20 h), we provided the antibacterial compound 5 days earlier in order to enrich the amount of isoniazid in the Drosophila body. As seen in Figure 3a , PAO1 killed flies within 48 h under isoniazid treatment, while flies that received heat-killed PAO1 showed no significant mortality. Furthermore, PAO1-GFP was disseminated into the entire body of the fly (Figure 3b ).
Drosophila mortality and curing are related to the number of bacteria in vivo
To determine whether M. marinum proliferated in the fly body, bacterial survival was measured in the presence or absence of the different antibiotics. For this, each infected fly was crushed, sampled and the number of bacteria was counted. Figure 4 demonstrates that M. marinum was capable of colonizing the flies and replicating inside the host, and the cfu showed significant differences between the groups. The smallest bacterial populations per fly were found to occur in the presence of rifampicin, dinitrobenzamide, amikacin and isoniazid (Figure 4) . Those antibiotics prevented the colonization of any detectable bacteria 11 days after injection, and this result was consistent with the observed fly survival rates (Figure 2 ). This result indicates that rifampicin, dinitrobenzamide, amikacin and isoniazid inhibited M. marinum growth in the fly body and extended the life span of infected flies. Because antimycobacterial regimens are typically administered in combination in the clinic, we also tested M. marinum dissemination after treatment with a drug combination of four different antibiotics. The drug combination showed the same bactericidal activity as the single treatments. Next, ethambutol-treated flies infected with M. marinum showed a moderate therapeutic effect (5600 cfu), but the infection was not eradicated. Lastly, pyrazinamide and ampicillin appear to be equally ineffective against M. marinum replication inside D. melanogaster (Figure 4) . The results of treatment with these two antibiotics showed a similar cfu per fly (10 750 and 10 150 cfu, respectively), which is not far from the cfu in untreated flies infected with M. marinum (11 000 cfu).
To confirm the colonization of M. marinum in flies under treatment with different kinds of antibiotics, we used an M. marinum strain carrying an integrated version of the GFP gene. Observation of GFP levels allowed us to follow the progression of bacterial colonization after curing through epifluorescence of anaesthetized flies. In flies treated with ampicillin or pyrazinamide and in the control flies, fluorescence could be detected Oh et al.
surrounding the site of pricking and was conspicuous in neighbouring regions such as the legs, body and head 13 days after infection with GFP-labelled M. marinum. The infection was observed to progress from the initial infection site eventually to multiplication of M. marinum in the whole Drosophila body cavity ( Figure 5 ). In contrast, flies treated with rifampicin, dinitrobenzamide, isoniazid and amikacin showed little or no GFP fluorescence. This result is in accordance with the survival curves and the cfu determination (Figures 2 and 4) .
The results presented here demonstrate the potential of the D. melanogaster-M. marinum infection model for testing drug efficacy. For the purposes of our study, we infected D. melanogaster via microinjection with standardized M. marinum inocula and assessed the effect of different oral antibiotics on fly survival and bacterial proliferation by determining the number of cfu. Interestingly, the first line of anti-TB drugs conferred significant protection and a reduction of bacterial cfus in flies infected with M. marinum. In contrast, treatment with ampicillin, which lacks antimycobacterial activity, had no impact on survival and bacterial burden in Drosophila flies infected with this mycobacterium.
The D. melanogaster -pathogen infection system has been used to study drug efficacy against other microorganisms. For example, Toll-deficient Drosophila flies fed with voriconazole, the preferred drug for treatment of invasive aspergillosis in humans, showed a significantly lower fungal burden and better survival of aspergillus infection. 37 Furthermore, fluconazole mixed into food significantly protected Toll-deficient Drosophila flies infected with fluconazole-susceptible Candida species, and S. aureus-infected flies were cured by treatment with methicillin and tetracycline. 11, 38 However, our model system is markedly different from the above-described previous experiments. We have tested the comprehensive drug regimens currently used to treat TB, including the first-line drugs (e.g. isoniazid, rifampicin, ethambutol, pyrazinamide) and a second-line drug (e.g. amikacin) along with newly discovered antitubercular drugs (e.g. dinitrobenzamide), including appropriate controls such as Pseudomonas infection/treatment with isoniazid. Single or combination antibiotic treatment showed a very strong curing effect on flies infected with M. marinum, providing support for the reliability and specificity of this model in antimycobacterial drug efficacy studies and for its adoption as a high-throughput screening method for the discovery of new compounds. Nonetheless, our model also has some obvious limitations. For example, M. marinum infection in flies gives no sign of formation of anything like a chronic granuloma, and there is the lack of a pneumonia model in flies. Furthermore, M. marinum is notable for having a different habitat from M. tuberculosis, and it does not typically cause human disease. However, M. marinum can induce lethal infection when injected into D. melanogaster, and this infection resembles the early stages of TB because M. marinum localize inside phagocytes where they then proceed to proliferate. In addition, later in infection, bacteria can escape via an unknown mechanism and can be found both inside and outside host cells. These two different JAC phenomena seem to be present from the very early stages of TB to the end stages of one form of miliary TB, which leads to death in humans. Furthermore, although flies do not have lungs, flies infected with M. marinum show human TB-like energy wasting. 17 M. marinum infections induce a pathological reduction in insulin signalling, and the flies appear to die from infection-induced wasting. Dionne et al. 17 suggested that this wasting response is in part the consequence of failure of activation of Akt and the consequent activation of the transcription factor FOXO. This Akt and FOXO dysregulation contribute to a disruption in insulin signalling in aspects of long-term energy storage. Flies infected with M. marinum do not properly phosphorylate Akt, resulting in a reduction in the level of insulin circulation or an increase in the turnover of activated Akt. This results in excessive levels of FOXO and Gsk-3, causing a progressive depletion of energy stores. However, Akt phosphorylation can be restored by injection of human insulin. This phenomenon is a typical characteristic observed in advanced TB. 17 In people, many infections such as TB and septic pathogenesis can be associated with insulin, hyperglycaemia and glucose intolerance. Septic patients are characterized by prominent metabolic derangements composed of high release and low use of glucose, amino acids and free fatty acids (FFAs), resulting in increased blood sugar levels; insulin therapy with exogenous insulin showed a dramatic increase in survival rates. 39 This type of glucose intolerance is also observed in pulmonary TB. 40 Thus, Dionne et al. suggested that the metabolic wasting observed in D. melanogaster infected with M. marinum may be a consequence of energy reallocation, and in humans infected with M. tuberculosis is also a consequence of sustained energy reallocation. 17 These results suggest that the fly can be used to study more than the immediate innate immune response to infection. We used the D. melanogaster-M. marinum infection model for M. tuberculosis drug screening, and this model showed efficacy results similar to those from the mouse model of infection. 41 In this context, utilization of the Drosophila host innate response to M. marinum infection can provide a physiological assessment of the mechanisms of drug action against mycobacterial pathogenesis. Furthermore, this methodology may be valuable in the rapid evaluation of the activity of new antimycobacterial agents.
